Prialt

(Ziconotide)

ApprovedPeptide

TTerezinha de Jesus Esteves Barata

Prialt is one of 113 small molecule programs targeting Neuropathic Pain. It is currently in Approved.

Indications

Total Trials

Active Trials

112

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

Cancer PainActive, not recruiting

Chronic PainActive, not recruiting

MyelopathyActive, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Cancer PainPreclinical

Active, not recruiting

Chronic PainPhase 2

Active, not recruiting

MyelopathyApproved

Active, not recruiting

Competition

Competitive Landscape

212 competitors in Neuropathic Pain

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Phase 3

4 2

Namenda

AbbVie

Phase 3

3 3

Prialt

TTerezinha de Jesus Esteves Barata

Approved

1 4

Briviact

UCB

Phase 3

1 5

Xylocaine

MMEDRx USA, Inc.

Phase 3

9 6

Sativex

Jazz Pharmaceuticals

Phase 3

6 7

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 8

Ultram

WWim Janssens

Phase 3

2 9

Ketalar

Boehringer Ingelheim

Phase 3

2 10

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Recruiting

Study completion

NCT04321408

Q4 2029

Recruiting

Cancer Pain

NCT06541184

Clinical

Trials by Indication[1]

Myelopathy1 trial

Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy

Withdrawn·AAaron Boster·Phase 4·NCT01992562

Chronic pain1 trial

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

Completed·NNeurex·Phase 2·NCT00002160·100 enrolled

Neuropathic Pain1 trial

Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT00996983·16 enrolled

GIST1 trial

Patient Registry of Intrathecal Ziconotide Management(PRIZM)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals··NCT01888120·93 enrolled

Effectiveness1 trial

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

Completed·EElan Pharmaceuticals·Phase 3·NCT00076544·300 enrolled

2 more indications

Cancer Pain1 trial

Ziconotide for Non-cancer Pain by Intrathecal Administration

Recruiting·EESTEVE Pharmaceuticals SAS··NCT06541184·85 enrolled

Unspecified2 trials

Intrathecal Bolus Doses of Ziconotide

Completed·UUniversity Hospital, Linkoeping·Phase 4·NCT01373983·26 enrolled

OP2C : Prialt® Observatory in Clinical Practice

Recruiting·IInstitut Cancerologie de l'Ouest··NCT04321408·300 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 28, 2004

PRIALT

NDA NDA021060

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ziconotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ziconotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ziconotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021060). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Terezinha de Jesus Esteves Barata company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Approved[1]
Company: TTerezinha de Jesus Esteves Barata

Prialt

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Trials by Indication[1]

Myelopathy1 trial

Chronic pain1 trial

Neuropathic Pain1 trial

GIST1 trial

Effectiveness1 trial

Cancer Pain1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News